NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Rivaroxaban (Xarelto): Treatment of Venous Thromboembolic Events (Deep Vein Thrombosis [DVT], Pulmonary Embolism [PE]) and Prevention of Recurrent DVT and PE [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2015 Aug.

APPENDIX 3EXCLUDED STUDIES

ReferenceReason for Exclusion
Agnelli G, et al. Circulation. 2007 Jul 10;116(2):180-7.
Buller HR. Ann Intern Med. 2012;157(4):JC4-6.		Not the intervention of interest
Douketis J. Ann Intern Med. 2011 May 17;154(10):JC5-6.Not a study design of interest
Cohen AT and Dobromirski M. Thromb Haemost. 2012 Feb 28;107(6):1035-43.Inappropriate control group
Copyright © CADTH 2015.

You are permitted to make copies of this document for non-commercial purposes, provided it is not modified when reproduced and appropriate credit is given to CADTH. You may not otherwise copy, modify, translate, post on a website, store electronically, republish, or redistribute any material from this document in any form or by any means without the prior written permission of CADTH.

Please contact CADTH’s Vice-President of Corporate Services at ac.htdac@secivresetaroproc with any inquiries about this notice or other legal matters relating to CADTH’s services.

Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/

Bookshelf ID: NBK344321
Contents